Forest’s LABA/LAMA Delay Gives GSK A Lengthy Lead On The Market
This article was originally published in The Pink Sheet Daily
Executive Summary
News that Forest/Almirall’s LABA/LAMA combination will be delayed due to a manufacturing issue means that GlaxoSmithKline’s Anoro Ellipta will continue to dominate the market as the sole fixed-dose combination available in the U.S.
You may also be interested in...
AstraZeneca Capitalizing On Respiratory With Actavis’ Divestiture
The British pharma is acquiring Actavis’ unwanted respiratory portfolio in a deal that will help AstraZeneca meet the $8 billion in revenues it expects to achieve from its respiratory franchise by 2023. For Actavis, it means unloading a handful of drugs that were underperforming and neglected.
Almirall Eyes Top Specialty Dermatology Role After its AstraZeneca Deal
Spain’s leading pharma company will use proceeds of its respiratory products sale to bulk up in dermatology, with the aim of becoming a global leader in the sector.
Boehringer’s Tiotropium Spray May Be Ready To Shed Mortality Issues
FDA Pulmonary-Allergy Drugs Advisory Committee to review NDA for COPD and will discuss safety results from trial comparing inhalation spray to powder.